Abstract
Malignant pleural mesothelioma (MPM) is a rare tumor with a poor prognosis. Blood biomarkers of MPM would be useful in clinical practice, as they could aid radiological evaluation by reflecting prognostic information and predicting the effects of treatment. The many reports on MPM blood biomarkers have focused on their utility as screening or diagnostic tests. Carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) have been used to aid in the diagnosis of MPM but are not useful as blood biomarkers. The most frequently studied blood biomarker of MPM is the soluble mesothelin-related peptides (SMRPs). Other potential biomarkers are megakaryocyte potentiating factor (MPF), also called N-ERV/mesothelin, which is formed from the same precursor protein as soluble mesothelin; osteopontin, a glycoprotein that mediates cell–matrix interactions; and fibulin-3, an extracellular glycoprotein. A combination of the best-performing marker and highest-value marker, as determined by ongoing research, will likely improve the accuracy and rapidity of MPM diagnosis in the near future.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362(9396):1612–6. https://doi.org/10.1016/S0140-6736(03)14794-0.
Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10(12 Pt 1):3937–42. https://doi.org/10.1158/1078-0432.CCR-03-0801.
Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol. 2008;3(11):1317–24. https://doi.org/10.1097/JTO.0b013e318187491c.
Creaney J, Dick IM, Segal A, Musk AW, Robinson BW. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer. 2013;82(3):491–8. https://doi.org/10.1016/j.lungcan.2013.09.016.
Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax. 2014;69(10):895–902. https://doi.org/10.1136/thoraxjnl-2014-205205.
Luo L, Shi HZ, Liang QL, Jiang J, Qin SM, Deng JM. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med. 2010;104(1):149–56. https://doi.org/10.1016/j.rmed.2009.05.017.
Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30(13):1541–9. https://doi.org/10.1200/JCO.2011.39.6671.
Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer. 2017;116(6):731–41. https://doi.org/10.1038/bjc.2017.22.
Tajima K, Hirama M, Shiomi K, Ishiwata T, Yoshioka M, Iwase A, et al. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma. Anticancer Res. 2008;28(6B):3933–6.
Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, De Vuyst P, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol. 2011;6(11):1930–7. https://doi.org/10.1097/JTO.0b013e3182272294.
Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014;120(21):3311–9. https://doi.org/10.1002/cncr.28875.
Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13(10):2928–35. https://doi.org/10.1158/1078-0432.CCR-06-2144.
Pass HI, Goparaju C, Espin-Garcia O, Donington J, Carbone M, Patel D, et al. Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2016;11(6):900–9. https://doi.org/10.1016/j.jtho.2016.02.006.
Mundt F, Heidari-Hamedani G, Nilsonne G, Metintas M, Hjerpe A, Dobra K. Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Biomed Res Int. 2014;2014:419853. https://doi.org/10.1155/2014/419853.
Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367(15):1417–27. https://doi.org/10.1056/NEJMoa1115050.
Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, et al. The south west area mesothelioma and pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. Br J Cancer. 2015;112(7):1175–82. https://doi.org/10.1038/bjc.2015.62.
Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol. 2010;5(4):479–83. https://doi.org/10.1097/JTO.0b013e3181d2f008.
Kao SC, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, et al. The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer. 2012;75(2):248–54. https://doi.org/10.1016/j.lungcan.2011.06.007.
Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science. 1989;243(4894 Pt 1):1056–9.
Lu B, Antoine DJ, Kwan K, Lundback P, Wahamaa H, Schierbeck H, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A. 2014;111(8):3068–73. https://doi.org/10.1073/pnas.1316925111.
Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72(13):3290–301. https://doi.org/10.1158/0008-5472.CAN-11-3481.
Wu T, Zhang W, Yang G, Li H, Chen Q, Song R, et al. HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget. 2016;7(31):50417–27. https://doi.org/10.18632/oncotarget.10413.
Jones DR. Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases. Br J Pharmacol. 2014;171(12):2925–39. https://doi.org/10.1111/bph.12601.
Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, et al. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms’ tumor and other human carcinomas. Cancer Res. 1993;53(6):1281–5.
Ak G, Tada Y, Shimada H, Metintas S, Ito M, Hiroshima K, et al. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin. BMC Cancer. 2017;17(1):212. https://doi.org/10.1186/s12885-017-3209-5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Isobe, K. (2019). Biomarkers of Malignant Pleural Mesothelioma. In: Shimada, H. (eds) Biomarkers in Cancer Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-13-7295-7_14
Download citation
DOI: https://doi.org/10.1007/978-981-13-7295-7_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-7294-0
Online ISBN: 978-981-13-7295-7
eBook Packages: MedicineMedicine (R0)